CN106236723A - A kind of roflumilast oral cavity disintegration tablet and preparation method thereof - Google Patents
A kind of roflumilast oral cavity disintegration tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106236723A CN106236723A CN201610823993.1A CN201610823993A CN106236723A CN 106236723 A CN106236723 A CN 106236723A CN 201610823993 A CN201610823993 A CN 201610823993A CN 106236723 A CN106236723 A CN 106236723A
- Authority
- CN
- China
- Prior art keywords
- parts
- roflumilast
- oral cavity
- white sugar
- disintegration tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
The invention discloses a kind of roflumilast oral cavity disintegration tablet and preparation method thereof.With roflumilast as effective ingredient, make oral cavity disintegration tablet medicament by the technique of innovation.Roflumilast oral cavity disintegration tablet prepared by the present invention successfully solves that drug dissolution is low and the problem such as medicine bitterness sense, has good effect for obstructive pulmonary disease (COPD) with chronic bronchitis.
Description
Technical field
The present invention relates to one and treat obstructive pulmonary disease (COPD) with the medicine of chronic bronchitis, be specifically related to one
Roflumilast oral cavity disintegration tablet and preparation method thereof, belongs to pharmaceutical technology field.
Background technology
Roflumilast is a kind of oral selectivity phosphodiesterase-4 (PDE4) inhibitor of Nycomed company exploitation,
For treating the medicine of a novel chronic obstructive pulmonary disease (COPD) of asthma and chronic obstructive pulmonary disease.Roflumilast
Mainly it is expressed in the inflammatory cell relevant with asthma, including eosinophilic granulocyte, neutrophilic granulocyte and mastocyte.This medicine can be special
Act on participate in smooth muscle contraction certain enzyme, can prevent cAMP from degrade, thus block proinflammatory signal transmission, have
Having anti-inflammatory activity, treatment asthma and chronic obstructive pulmonary disease obtain preferable curative effect clinically.Roflumilast can also be bright
The aobvious deterioration delaying Respiratory symptoms, is greatly enhanced the quality of life of patient simultaneously
This medicine has been proven to the inflammation relevant with (COPD) with a kind of brand-new model of action suppression.As one day
Oral tablet once, roflumilast is not only the first medicine in serious COPD new therapy, and be the first towards
The oral anti-inflammatory agent of COPD patient.The character of its uniqueness, contributes to preferably treating patients with chronic obstructive pulmonary diseases: when with
Trachea expanding agent drug combination treat severe chronic obstructive pulmonary disease time, roflumilast can provide and reduce disease further
Shape and the additional benefit of disease progression rate, thus become targeting particular phenotype chronic obstructive pulmonary disease i.e. exist with chronic cough and
Serious flow limitation that excessive phlegm is relevant and have first medicine of disease progression history patient repeatedly.
In July, 2010 is approved roflumilast for for serious chronic obstructive pulmonary disease (COPD) and slow in European Union
Property bronchitis, trade name Daxas；On February 28th, 2011, U.S. FDA approval roflumilast is used for serious COPD treatment,
Trade name Daliresp.Thus become ten be approved the most in the world for chronic obstructive pulmonary disease treatment first
Individual new oral medicine.Nycomed company roflumilast gross sales amount in 2010 is 3,800,000 Euros.Relevant analyst predicts,
European Union area, roflumilast listing sales volume then is 7,000,000 Euros, can rise to 1.50 hundred million Euros by 2015.
For the patient of dysphagia, particularly child and old man, exploitation one both safe and effective, taking conveniences, again can
Ensure that dosage product accurately is very important.
Summary of the invention
For the deficiencies in the prior art, the present invention provides a kind of roflumilast oral cavity disintegration tablet and preparation method thereof, by innovation
Adjuvant select and the auxiliary material proportion that optimizes and the preparation technology of innovation, successfully solve that drug dissolution is low and medicine is bitter
The problems such as astringent sense.
Technical solution of the present invention is as follows:
A kind of roflumilast oral cavity disintegration tablet, is made up by mass parts of following raw material:
| Roflumilast | 2～20 parts |
| Fatty glyceride | 10～30 parts |
| Tween 80 | 5～10 parts |
| White sugar | 900～2700 parts |
| Polyvinylpolypyrrolidone | 2～5 parts |
| Mannitol | 10～30 parts |
| Essence | 0.01～0.05 part |
| Magnesium stearate | 0.2～0.5 part |
| Micropowder silica gel | 0.2～0.5 part |
According to the invention it is preferred to:
A kind of roflumilast oral cavity disintegration tablet, is made up by mass parts of following raw material:
| Roflumilast | 2～15 parts |
| Fatty glyceride | 10～25 parts |
| Tween 80 | 5～8 parts |
| White sugar | 900～2300 parts |
| Polyvinylpolypyrrolidone | 2～4 parts |
| Mannitol | 10～25 parts |
| Essence | 0.01～0.04 part |
| Magnesium stearate | 0.2～0.4 part |
| Micropowder silica gel | 0.2～0.4 part |
According to the present invention, further preferred that
A kind of roflumilast oral cavity disintegration tablet, is made up by mass parts of following raw material:
| Roflumilast | 5 parts |
| Fatty glyceride | 10 parts |
| Tween 80 | 5 parts |
| White sugar | 1000 parts |
| Polyvinylpolypyrrolidone | 2 parts |
| Mannitol | 10 parts |
| Essence | 0.01 part |
| Magnesium stearate | 0.2 part |
| Micropowder silica gel | 0.2 part |
Or, a kind of roflumilast oral cavity disintegration tablet, it is made up by mass parts of following raw material:
| Roflumilast | 15 parts |
| Fatty glyceride | 25 parts |
| Tween 80 | 8 parts |
| White sugar | 2000 parts |
| Polyvinylpolypyrrolidone | 4 parts |
| Mannitol | 25 parts |
| Essence | 0.04 part |
| Magnesium stearate | 0.4 part |
| Micropowder silica gel | 0.4 part |
Or, a kind of roflumilast oral cavity disintegration tablet, it is made up by mass parts of following raw material:
| Roflumilast | 2.5 part |
| Fatty glyceride | 10 parts |
| Tween 80 | 5 parts |
| White sugar | 907.5 part |
| Polyvinylpolypyrrolidone | 2 parts |
| Mannitol | 10 parts |
| Essence | 0.01 part |
| Magnesium stearate | 0.2 part |
| Micropowder silica gel | 0.2 part |
Roflumilast oral cavity disintegration tablet of the present invention, what the raw material that used was not specified is conventional commercial products.
The preparation method of a kind of roflumilast oral cavity disintegration tablet, comprises the steps:
(1) roflumilast is pulverized, cross 140～160 mesh sieves, obtain the granule that mean diameter is 21～45 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 100～120 mesh sieves, standby；
(3) fatty glyceride is melted at 60 DEG C～80 DEG C, after adding the Tween 80 mixing of proportional quantity, weigh sieve of proportional quantity
Fluorine department is special, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 10～20 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to 50～the mixed solution of 60% (W/W), be subsequently adding step (3)
After material, fully mixing, put in freeze drying box；Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution to be mixed
Temperature is down to-30 DEG C～-40 DEG C, and pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature to-10 DEG C～-15
DEG C, it is vacuum dried 15～20 hours；Raising shelf temperature is to 30 DEG C～40 DEG C again, keeps 1～2 hour, and vacuum maintains 0
～10Pa, until goods moisture terminates in 2～6% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity and deionized water are mixed, add the white sugar of remaining 2/3, heat up after 60～80 DEG C,
It is down to room temperature, pelletizes；Then dry for 50～60 DEG C, be 2%～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
According to currently preferred, the roflumilast described in step (1) is pulverized, and crosses 150～160 mesh sieves, uses laser
Granulometry obtains mean diameter in 21～32 μm.
According to currently preferred, the goods moisture described in step (4), control at 2%～5% (W/W).
According to the present invention it is further preferred that the preparation method of a kind of roflumilast oral cavity disintegration tablet, comprise the steps:
(1) being pulverized by roflumilast, cross 150 mesh sieves, obtaining mean diameter is 28～32 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 110 mesh sieves, standby；
(3) fatty glyceride is melted at 60 DEG C～80 DEG C, after adding the mixing of proportional quantity Tween 80, weigh sieve fluorine of proportional quantity
Department spy, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 15 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to the mixed solution of 55% (W/W), be subsequently adding the material of step (3),
Fully after mixing, put in freeze drying box.Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution temperature to be mixed
Being down to-30 DEG C～-40 DEG C, pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature extremely-10 DEG C～-15 DEG C,
It is vacuum dried 15～20 hours；Again improve shelf temperature to 30 DEG C～40 DEG C, keep 1～2 hour, vacuum maintain 0～
10Pa, until goods moisture terminates in 2～5% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity is mixed with deionized water, add the white sugar of remaining 2/3, heat up 60 DEG C～80 DEG C
After, it is down to room temperature, pelletizes；Dry at 50 DEG C～60 DEG C, be 2%～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
Room temperature of the present invention means 10～30 DEG C.
Detailed description of the invention
Below by specific embodiment, the present invention will be further described, but is not limited to this.
Device involved in embodiment and equipment are solid preparation and produce common apparatus, and market is commercially available, is described as follows:
Universal high-efficiency pulverizer (model 30B), square shaking screen (model FS-0.5M2-X), high-speed mixing granulating machine (model
GHL200), rotary granulator (model ZLB series 300D), three-dimensional motion mixer (model SYH-800) above equipment: often
State city Teng Longyaohua equipment company limited is on sale.Laser particle size analyzer (model Mastersizer3000) (Britain).Freeze dryer
(model LGJ-200F) Beijing development in science and technology company limited of Song Yuan Huaxing is on sale.Particle packaging machine (model YO-F100) Shanghai sunlight
Europe particles packing machine factory is on sale.Full-automatic double charging high speed tablet press (model GZPS-49): Beijing member of Imperial Academy's space flight development in science and technology stock
Part company is on sale.
Below in conjunction with specific embodiment, the present invention will be further described.Should be understood that following example are merely to illustrate this
Invention, not for limiting the scope of the present invention.
Embodiment 1, the preparation method of a kind of roflumilast oral cavity disintegration tablet
1, a kind of roflumilast oral cavity disintegration tablet, is made up by mass parts of following raw material:
| Roflumilast | 5 parts |
| Fatty glyceride | 10 parts |
| Tween 80 | 5 parts |
| White sugar | 905 parts |
| Polyvinylpolypyrrolidone | 2 parts |
| Mannitol | 10 parts |
| Essence | 0.01 part |
| Magnesium stearate | 0.2 part |
| Micropowder silica gel | 0.2 part |
Preparation method is as follows:
(1) being pulverized by roflumilast, cross 150 mesh sieves, obtaining mean diameter is 28～32 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 110 mesh sieves, standby；
(3) fatty glyceride is melted at 60～80 DEG C, after adding the mixing of proportional quantity Tween 80, weigh sieve fluorine department of proportional quantity
Spy, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 15 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to the mixed solution of 55% (W/W), be subsequently adding the material of step (3),
Fully after mixing, put in freeze drying box.Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution temperature to be mixed
Being down to-30 DEG C～-40 DEG C, pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature extremely-10 DEG C～-15 DEG C,
Slowly heat up vacuum drying 15～20 hours；Raising shelf temperature is to 30 DEG C～40 DEG C again, keeps 1～2 hour, and vacuum is tieed up
Hold 0～10Pa, until goods moisture terminates in 2～5% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity and deionized water are mixed, add the white sugar of remaining 2/3, heat up after 60～80 DEG C,
It is down to room temperature, pelletizes；Dry at 50～60 DEG C, be 2～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
Embodiment 2, the preparation method of a kind of roflumilast oral cavity disintegration tablet
1, a kind of roflumilast oral cavity disintegration tablet, is made up by mass parts of following raw material:
| Roflumilast | 25 parts |
| Fatty glyceride | 25 parts |
| Tween 80 | 8 parts |
| White sugar | 2100 parts |
| Polyvinylpolypyrrolidone | 4 parts |
| Mannitol | 25 parts |
| Essence | 0.04 part |
| Magnesium stearate | 0.4 part |
| Micropowder silica gel | 0.4 part |
Preparation method is as follows:
(1) roflumilast is pulverized, cross 160 mesh sieves, obtain the granule that mean diameter is 21～24 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 100 mesh sieves, standby；
(3) fatty glyceride is melted at 60～80 DEG C, after adding the Tween 80 mixing of proportional quantity, weigh sieve fluorine of proportional quantity
Department spy, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 20 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to the mixed solution of 60% (W/W), be subsequently adding the material of step (3),
Fully after mixing, put in freeze drying box；Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution temperature to be mixed
Being down to-30 DEG C～-40 DEG C, pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature extremely-10 DEG C～-15 DEG C,
Slowly heat up vacuum drying 15～20 hours；Raising shelf temperature is to 30 DEG C～40 DEG C again, keeps 1～2 hour, and vacuum is tieed up
Hold 0～10Pa, until goods moisture terminates in 2～5% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity and deionized water are mixed, add the white sugar of remaining 2/3, heat up after 60～80 DEG C,
It is down to room temperature, pelletizes；Then dry for 50～60 DEG C, be 2～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
Embodiment 3, the preparation method of a kind of roflumilast oral cavity disintegration tablet
1, a kind of roflumilast oral cavity disintegration tablet, is made up by mass parts of following raw material:
| Roflumilast | 2.5 part |
| Fatty glyceride | 10 parts |
| Tween 80 | 5 parts |
| White sugar | 907.5 part |
| Polyvinylpolypyrrolidone | 2 parts |
| Mannitol | 10 parts |
| Essence | 0.01 part |
| Magnesium stearate | 0.2 part |
| Micropowder silica gel | 0.2 part |
Preparation method is as follows:
(1) roflumilast is pulverized, cross 155 mesh sieves, obtain the granule that mean diameter is 24～28 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 120 mesh sieves, standby；
(3) fatty glyceride is melted at 60～80 DEG C, after adding the Tween 80 mixing of proportional quantity, weigh sieve fluorine of proportional quantity
Department spy, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 10 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to the mixed solution of 50% (W/W), be subsequently adding the material of step (3),
Fully after mixing, put in freeze drying box；Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution temperature to be mixed
Being down to-30 DEG C～-40 DEG C, pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature extremely-10 DEG C～-15 DEG C,
Slowly heat up vacuum drying 15～20 hours；Raising shelf temperature is to 30 DEG C～40 DEG C again, keeps 1～2 hour, and vacuum is tieed up
Hold 0～10Pa, until goods moisture terminates in 2～5% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity and deionized water are mixed, add the white sugar of remaining 2/3, heat up after 60～80 DEG C,
It is down to room temperature, pelletizes；Then dry for 50～60 DEG C, be 2～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
Claims (4)
1. a roflumilast oral cavity disintegration tablet, it is characterised in that be made up by mass parts of following raw material:
Roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that be made up by mass parts of following raw material:
Roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that be made up by mass parts of following raw material:
Roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that be made up by mass parts of following raw material:
Roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that be made up by mass parts of following raw material:
The preparation method of the roflumilast oral cavity disintegration tablet as described in the claims are arbitrary, comprises the steps:
(1) roflumilast is pulverized, cross 140～160 mesh sieves, obtain the granule that mean diameter is 21～45 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 100～120 mesh sieves, standby；
(3) fatty glyceride is melted at 60～80 DEG C, after adding the Tween 80 mixing of proportional quantity, weigh sieve fluorine of proportional quantity
Department spy, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 10～20 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to 50～the mixed solution of 60% (W/W), be subsequently adding step (3)
After material, fully mixing, put in freeze drying box；Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution to be mixed
Temperature is down to-30 DEG C～-40 DEG C, and pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature to-10 DEG C～-15
DEG C, it is vacuum dried 15～20 hours；Raising shelf temperature is to 30 DEG C～40 DEG C again, keeps 1～2 hour, and vacuum maintains
0～10Pa, until goods moisture terminates in 2～6% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity and deionized water are mixed, add the white sugar of remaining 2/3, heat up after 60～80 DEG C,
It is down to room temperature, pelletizes；Then dry for 50～60 DEG C, be 2～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
2. the preparation method of the roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that sieve described in step (1)
Fluorine department spy pulverizes, and crosses 150～160 mesh sieves.
3. the preparation method of the roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that the system described in step (4)
Product moisture, controls 2～5% (W/W).
4. the preparation method of the roflumilast oral cavity disintegration tablet as described in the claims, it is characterised in that comprise the steps:
(1) being pulverized by roflumilast, cross 150 mesh sieves, obtaining mean diameter is 28～32 μm, standby；
(2) white sugar of proportional quantity, polyvinylpolypyrrolidone are pulverized, cross 110 mesh sieves, standby；
(3) fatty glyceride is melted at 60～80 DEG C, after adding the mixing of proportional quantity Tween 80, weigh sieve fluorine department of proportional quantity
Spy, adds 1/3 (W/W) white sugar of proportional quantity, after room temperature cooling and solidifying, pulverized 15 mesh sieves；
(4) mannitol is dissolved in deionized water it is configured to the mixed solution of 55% (W/W), be subsequently adding the material of step (3),
Fully after mixing, put in freeze drying box；Open freeze dryer, lyophilizing shelf is down to-40 DEG C～-50 DEG C, solution temperature to be mixed
Being down to-30 DEG C～-40 DEG C, pre-freeze is incubated 2～3 hours；Start evacuation, then step up temperature extremely-10 DEG C～-15 DEG C,
It is vacuum dried 15～20 hours；Again improve shelf temperature to 30 DEG C～40 DEG C, keep 1～2 hour, vacuum maintain 0～
10Pa, until goods moisture terminates in 2～5% (W/W) lyophilizing, outlet and get final product；
(5) polyvinylpolypyrrolidone of proportional quantity and deionized water are mixed, add the white sugar of remaining 2/3, heat up after 60～80 DEG C,
It is down to room temperature, pelletizes；Dry at 50～60 DEG C, be 2～6% (W/W) to moisture；
(6) step (4) and (5) granule are mixed with essence, magnesium stearate, micropowder silica gel, tabletting, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610823993.1A CN106236723A (en) | 2016-09-17 | 2016-09-17 | A kind of roflumilast oral cavity disintegration tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610823993.1A CN106236723A (en) | 2016-09-17 | 2016-09-17 | A kind of roflumilast oral cavity disintegration tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106236723A true CN106236723A (en) | 2016-12-21 |
Family
ID=57599768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610823993.1A Pending CN106236723A (en) | 2016-09-17 | 2016-09-17 | A kind of roflumilast oral cavity disintegration tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106236723A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330689A (en) * | 1998-12-18 | 2002-01-09 | 美国拜尔公司 | Thermoplastic composition suitable for optical applications having low haze valus |
| CN102743353A (en) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | Roflumilast tablet preparation and preparation method thereof |
| CN105560199A (en) * | 2016-03-01 | 2016-05-11 | 山东司邦得制药有限公司 | Infantile domperidone orally disintegrating tablet and preparation method thereof |
-
2016
- 2016-09-17 CN CN201610823993.1A patent/CN106236723A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330689A (en) * | 1998-12-18 | 2002-01-09 | 美国拜尔公司 | Thermoplastic composition suitable for optical applications having low haze valus |
| CN102743353A (en) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | Roflumilast tablet preparation and preparation method thereof |
| CN105560199A (en) * | 2016-03-01 | 2016-05-11 | 山东司邦得制药有限公司 | Infantile domperidone orally disintegrating tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李全林: "《新医药开发与研究》", 31 December 2008, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015157851A5 (en) | ||
| CN102793733B (en) | Ginseng royal jelly chewable tablets and preparation method thereof | |
| JP2015166379A5 (en) | ||
| CN102764264A (en) | Celecoxib solid composition with high dissolution, preparation method and application | |
| CN106389369A (en) | Ferrous fumarate folic acid compound film coated tablet preparation method | |
| WO2016161991A2 (en) | Clopidogrel bisulphate solid preparation and preparation method therefor | |
| CN103536538B (en) | A kind of expansive pellet of effective taste masking and preparation method thereof | |
| CN103127011B (en) | Roflumilast tablet and preparation method thereof | |
| CN105287413A (en) | Chewable tablet containing montelukast sodium and preparation method of chewable tablet | |
| CN101015519B (en) | Loratadine oral compound medication composition | |
| CN106236723A (en) | A kind of roflumilast oral cavity disintegration tablet and preparation method thereof | |
| CN106176647A (en) | A kind of fertile for western spit of fland oral cavity disintegration tablet and preparation method thereof | |
| CN104887634A (en) | Olanzapine orally disintegrating tablets and preparation method thereof | |
| CN101284011B (en) | Oleanolic acid orally disintegrating tablet and preparation method thereof | |
| KR101585705B1 (en) | Novel method for preparing granulates of active principles, and granulates obtained thereof | |
| CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
| CN103142604B (en) | Acetaminophen and caffeine dispersible tablet, and its preparation method | |
| CN102626410A (en) | Pharmaceutical composition containing roflumilast | |
| CN104098489A (en) | Micronized glibenclamide and composition thereof | |
| CN102058549B (en) | Finasteride-containing orally disintegrating tablets and preparation method thereof | |
| CN102204910B (en) | Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof | |
| CN110772490A (en) | Preparation method of apixaban tablets | |
| CN101757475A (en) | Method for preparing fresh snow preparation | |
| CN101297869A (en) | Gastralgia dispersed tablet and preparation | |
| KR100735904B1 (en) | Tablet composition containing extract of natural herbal plants and its manufacturing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161221 |
|
| WD01 | Invention patent application deemed withdrawn after publication |